Chief Human Resources Officer — Quality And Supply Network

The mandate

A pharmaceutical enterprise has reprioritised its late-stage pipeline after new clinical evidence changed launch sequence and demand scenarios. Its quality-and-supply network was designed for the previous portfolio: some scarce technical skills are now required sooner, while other teams face reduced or uncertain work. An urgent replacement must reshape capability without destabilising compliant supply.

Approximately 1,075 employees and material partners work across quality assurance, quality control, manufacturing science, planning, external supply, logistics and site operations from Copenhagen across the wider network. The CHRO owns workforce strategy, organisation, talent, reward, employee relations and people operations, reporting to the Group Chief Executive or nominated sponsor. Quality and technical release authority remains independent.

The workforce baseline must connect roles to products, technologies and obligations. Job titles do not reveal whether a person can lead aseptic validation, investigate analytical drift or qualify an external supplier. The CHRO will build a capability map with technical leaders, including proficiency, authorisation, transferability and time to competence.

Pipeline scenarios will drive establishment. Positive, delayed and discontinued outcomes require different staffing by site and function. The CHRO will create trigger-based plans rather than hire against one optimistic forecast. Contingent capacity, internal mobility and external partners should preserve options without obscuring accountability.

Critical knowledge needs protection before change is announced. Senior specialists may hold process rationale, regulatory history or supplier knowledge not captured in procedures. Retention decisions will identify specific transfer outcomes and successors. Blanket payments are inadequate; observed independent performance will demonstrate transfer.

Quality independence must survive organisation redesign. Removing layers or combining functions cannot create pressure on release, deviation or audit decisions. The CHRO will assess reporting, objectives, reward and escalation with the quality leader. A cost target will not determine whether a control role remains necessary.

Site and network leadership accountabilities will be reset. Product-focused teams, platform experts and site operations often compete for scarce resources. The CHRO will clarify who sets technical standards, who allocates capacity and who decides deviations in plan. Real scenario testing will reveal ambiguity before a launch or shortage does.

Employee relations require early, country-specific engagement. Reprioritisation may involve redeployment, role change, recruitment and reduction across several jurisdictions. The CHRO will sequence consultation and communication truthfully, distinguishing decided changes from scenarios. Managers will receive evidence and support before speaking with teams.

Mobility should build capability, not merely fill vacancies. Assignments between development, commercial supply and external partners need objectives, supervision and return paths. Employees moving into regulated responsibilities must complete required qualification before independent work. Workforce urgency cannot bypass training evidence.

Reward can create unwanted portfolio advocacy. Leaders whose incentives depend heavily on one programme may resist stopping or redeploying. The CHRO will rebalance objectives towards enterprise readiness, quality, transfer and decision quality. Speaking up about unrealistic schedules must be recognised, not treated as lack of commitment.

Workload and wellbeing have compliance consequences. Inspection preparation, technology transfer and launch work can produce prolonged overtime and error risk. The CHRO will connect hours, absence, turnover and quality signals, requiring staffing or schedule intervention. Generic wellbeing offers cannot compensate for an impossible operating plan.

External partners carry critical skills but cannot become hidden permanent establishment. The CHRO will ensure supplier roles, access, training and knowledge ownership are clear. Where capability is strategically essential, a build-or-buy decision should be explicit and include succession.

People data and access changes must be controlled. A role move can alter training, system access and authorised tasks. Joiner-mover-leaver processes will connect HR, quality and technology records, preventing someone from retaining authority or losing required access inadvertently.

What you will own

• Scenario-based quality-and-supply workforce strategy.
• Technical capability, authorisation and succession mapping.
• Organisation design preserving quality independence.
• Critical-knowledge retention and verified transfer.
• Employee relations, mobility and redeployment.
• Reward, workload and leadership accountability.
• External workforce and strategic capability choices.
• People operations linked to regulated access.

The first 12 months

Within 45 days, map launch-critical skills, identify single points of knowledge and test workforce plans against pipeline scenarios. Protect any quality or supply capability at immediate risk.

By month six, implement trigger-based establishment, complete priority consultations and launch supervised mobility and knowledge transfer. Reset executive objectives around enterprise portfolio decisions.

At twelve months, achieve 95% qualified coverage for launch-critical roles, reduce single-person technical dependencies by 60% and fill 70% of priority capabilities through internal development or transfer. Regretted loss in identified critical talent should remain below 8%, with zero quality lapse caused by unqualified deployment or uncontrolled role access.

What the sponsor will examine

• Skills mapped to technologies and authorisations.
• Workforce plans changing with pipeline evidence.
• Quality independence protected through redesign.
• Knowledge transfer proven through independent work.
• Employee consultation preceding implementation.
• Workload risk reflected in launch schedules.

The person

You bring 22–28 years in people leadership, including CHRO or major-network accountability in pharmaceuticals, biotechnology or another regulated manufacturing environment. Your record includes pipeline reprioritisation, quality or supply workforce design, multi-country employee relations and technical succession.

Candidates must demonstrate a workforce change where compliance constraints altered the preferred organisation answer. Danish and wider European employee-relations experience are valuable. This permanent replacement is onsite in Copenhagen with international site engagement.

Compensation and terms

Base compensation is DKK 2,550,000–3,500,000 plus annual incentive and long-term participation tied to capability readiness, quality independence, retention, workforce delivery and leadership. The permanent onsite Copenhagen role reports to the Group Chief Executive or nominated executive-committee sponsor. Replacement is urgent during portfolio reprioritisation.

Confidentiality

The enterprise, assets, pipeline data, employees, sites, quality systems, suppliers and workforce plans remain confidential. Further detail follows conflicts and signed confidentiality. Applicants must not approach pharmaceutical companies, sites or employees to infer the client.